Kaken Pharmaceutical Co Ltd
TSE:4521
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
3 250
4 561
|
| Price Target |
|
We'll email you a reminder when the closing price reaches JPY.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Kaken Pharmaceutical Co Ltd
Gross Profit
Kaken Pharmaceutical Co Ltd
Gross Profit Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Gross Profit | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
K
|
Kaken Pharmaceutical Co Ltd
TSE:4521
|
Gross Profit
¥52.9B
|
CAGR 3-Years
9%
|
CAGR 5-Years
0%
|
CAGR 10-Years
2%
|
|
|
Takeda Pharmaceutical Co Ltd
TSE:4502
|
Gross Profit
¥3T
|
CAGR 3-Years
8%
|
CAGR 5-Years
10%
|
CAGR 10-Years
9%
|
|
|
Daiichi Sankyo Co Ltd
TSE:4568
|
Gross Profit
¥1.3T
|
CAGR 3-Years
26%
|
CAGR 5-Years
18%
|
CAGR 10-Years
9%
|
|
|
Otsuka Holdings Co Ltd
TSE:4578
|
Gross Profit
¥1.6T
|
CAGR 3-Years
18%
|
CAGR 5-Years
12%
|
CAGR 10-Years
4%
|
|
|
Chugai Pharmaceutical Co Ltd
TSE:4519
|
Gross Profit
¥805.2B
|
CAGR 3-Years
11%
|
CAGR 5-Years
15%
|
CAGR 10-Years
13%
|
|
|
Astellas Pharma Inc
TSE:4503
|
Gross Profit
¥1.4T
|
CAGR 3-Years
12%
|
CAGR 5-Years
7%
|
CAGR 10-Years
5%
|
|
Kaken Pharmaceutical Co Ltd
Glance View
Founded in 1948, Kaken Pharmaceutical Co., Ltd. is a prominent player in Japan's pharmaceutical landscape, seamlessly blending tradition with innovation. The company's journey began amidst post-war economic rebuilding, initially catering to the nation's healthcare needs with basic medicines. Over the years, it has carved out a niche for itself, specializing in the development, manufacturing, and commercialization of a wide range of pharmaceutical products. Kaken's focus areas include dermatology, orthopedics, and surgery, with a strong emphasis on treatments for fungal infections and inflammation management. This specialization has propelled the company into a position of leadership, especially in the dermatology market, where its expertise in topical formulations excels. Kaken Pharmaceutical monetizes its ventures primarily through the sale of prescription and over-the-counter drugs, leveraging a robust distribution network that extends its reach across Japan and international markets. The company continually reinvests in research and development to sustain its competitive edge, regularly introducing innovative therapies that address unmet medical needs. While pharmaceuticals remain its core revenue stream, Kaken also generates income from its chemical businesses, which include agrochemicals and animal health products, further diversifying its portfolio. By maintaining a balanced blend of traditional pharmaceutical sales and chemical product lines, Kaken ensures steady financial footing while advancing health solutions for a global audience.
See Also
What is Kaken Pharmaceutical Co Ltd's Gross Profit?
Gross Profit
52.9B
JPY
Based on the financial report for Sep 30, 2024, Kaken Pharmaceutical Co Ltd's Gross Profit amounts to 52.9B JPY.
What is Kaken Pharmaceutical Co Ltd's Gross Profit growth rate?
Gross Profit CAGR 10Y
2%
Over the last year, the Gross Profit growth was 36%. The average annual Gross Profit growth rates for Kaken Pharmaceutical Co Ltd have been 9% over the past three years , and 2% over the past ten years .
You don't have any saved screeners yet
